糖尿病风险表型与COVID-19严重程度及死亡的关联:一项动态系统综述与meta分析
该动态系统综述与meta分析纳入22篇观察性研究共17687例糖尿病患者,评估糖尿病相关表型与COVID-19严重程度及死亡的关联。结果显示男性、年龄>65岁、心血管疾病、慢性肾脏病、慢性阻塞性肺疾病、胰岛素使用及入院血糖≥11 mmol/l与COVID-19死亡风险升高相关,二甲双胍使用与死亡风险降低相关;与严重程度的关联类似但较弱。
要点
- 年龄>65岁、男性、心血管疾病、慢性肾脏病、COPD及胰岛素使用与糖尿病患者COVID-19死亡风险升高相关。
- 二甲双胍使用与糖尿病患者COVID-19死亡风险降低相关(SRR 0.50)。
- 入院血糖≥11 mmol/l与COVID-19死亡风险显著升高相关(SRR 8.60)。
核心结论
- 糖尿病病程更严重的个体相比病程较轻者,COVID-19预后更差。
研究设计与样本
- 动态系统综述与meta分析,检索四个数据库至2020年10月10日,纳入22篇观察性研究共17687例糖尿病患者,采用随机效应模型计算汇总相对风险(SRR)及95%CI,用GRADE工具评价证据确定性。
主要发现
- 男性与COVID-19死亡相关(SRR 1.28 [95%CI 1.02, 1.61],n=10项研究)。
- 年龄>65岁与COVID-19死亡相关(SRR 3.49 [95%CI 1.82, 6.69],n=6项研究)。
- 心血管疾病(SRR 1.56 [95%CI 1.09, 2.24],n=8)、慢性肾脏病(SRR 1.93 [95%CI 1.28, 2.90],n=6)、COPD(SRR 1.40 [95%CI 1.21, 1.62],n=5)与COVID-19死亡相关。
- 胰岛素使用与COVID-19死亡相关(SRR 1.75 [95%CI 1.01, 3.03],n=5),二甲双胍使用与死亡风险降低相关(SRR 0.50 [95%CI 0.28, 0.90],n=4)。
- 入院血糖≥11 mmol/l与COVID-19死亡相关(SRR 8.60 [95%CI 2.25, 32.83],n=2项研究)。
关键数值与推荐
- 男性、年龄>65岁、心血管疾病、慢性肾脏病、COPD、胰岛素使用及入院血糖≥11 mmol/l与COVID-19死亡风险升高相关(证据确定性高至中等)。
- 二甲双胍使用与COVID-19死亡风险降低相关(SRR 0.50 [95%CI 0.28, 0.90])。
- 风险表型与COVID-19严重程度的关联类似但普遍较弱且精确度较低。
临床怎么用
- 对合并男性、高龄、心血管疾病、慢性肾脏病、COPD或使用胰岛素的糖尿病患者,应加强COVID-19风险评估与监测。
- 入院血糖≥11 mmol/l提示COVID-19死亡风险显著升高,需重视血糖管理。
局限性
- 证据来自观察性研究,可能存在潜在混杂因素。
- 部分关联的精确度较低(如入院血糖≥11 mmol/l仅基于2项研究)。
- 需更多控制潜在混杂因素的研究以进一步强化证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes has been identified as a risk factor for poor prognosis of coronavirus disease-2019 (COVID-19). The aim of this study is to identify high-risk phenotypes of diabetes associated with COVID-19 severity and death. METHODS: This is the first edition of a living systematic review and meta-analysis on observational studies investigating phenotypes in individuals with diabetes and COVID-19-related death and severity. Four different databases were searched up to 10 October 2020. We used a random effects meta-analysis to calculate summary relative risks (SRR) with 95% CI. The certainty of evidence was evaluated by the GRADE tool. RESULTS: A total of 22 articles, including 17,687 individuals, met our inclusion criteria. For COVID-19-related death among individuals with diabetes and COVID-19, there was high to moderate certainty of evidence for associations (SRR [95% CI]) between male sex (1.28 [1.02, 1.61], n = 10 studies), older age (>65 years: 3.49 [1.82, 6.69], n = 6 studies), pre-existing comorbidities (cardiovascular disease: 1.56 [1.09, 2.24], n = 8 studies; chronic kidney disease: 1.93 [1.28, 2.90], n = 6 studies; chronic obstructive pulmonary disease: 1.40 [1.21, 1.62], n = 5 studies), diabetes treatment (insulin use: 1.75 [1.01, 3.03], n = 5 studies; metformin use: 0.50 [0.28, 0.90], n = 4 studies) and blood glucose at admission (≥11 mmol/l: 8.60 [2.25, 32.83], n = 2 studies). Similar, but generally weaker and less precise associations were observed between risk phenotypes of diabetes and severity of COVID-19. CONCLUSIONS/INTERPRETATION: Individuals with a more severe course of diabetes have a poorer prognosis of COVID-19 compared with individuals with a milder course of disease. To further strengthen the evidence, more studies on this topic that account for potential confounders are warranted. REGISTRATION: PROSPERO registration ID CRD42020193692.
引用
- Schlesinger S, Neuenschwander M, Lang A, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021. PMID: 33907860. doi:10.1007/s00125-021-05458-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。